- localised and advanced localised prostate cancer
- castrate resistant prostate cancer
- intensity modulated radiotherapy
- clinical trials
Professor David Dearnaley joined the Academic Unit of Radiotherapy at The Royal Marsden and The Institute of Cancer Research (ICR) as Bob Champion Senior Lecturer and Honorary Consultant in 1987. He subsequently became Reader in Prostate Cancer Studies in 1999 and Professor of Uro-Oncology in 2003.
He was Head of The Royal Marsden's Urology Unit from 1994 to 2006 and Chairman of The Royal Marsden and ICR Committee for Clinical Research from 2006 to 2013. He is the Prostate Theme Lead for The Royal Marsden / ICR Biomedical Research Centre. He was appointed an NIHR Senior Investigator in 2008 and is a member of the NHS HTA Clinical Trials Board College of Experts. He has previously chaired both the MRC and NCRI Prostate Study Groups, as well as the MRC Radiotherapy Clinical Trials Group.
Principal areas of research have been in the development of conformal (CFRT), intensity-modulated (IMRT) and image-guided (IGRT) radiotherapy treatments for prostate cancer. He has led Phase III randomised trials to establish these in clinical practice and is the chief investigator leading a multi-centre trial of IMRT using hypofractionated schedules; known as CHHiP. This is the largest academic treatment trial completed in prostate cancer. The results of his conformal and dose escalation studies in prostate cancer have been incorporated in NICE guidance. Presently he leads associated translational programmes into the biophysics, radiogenomics and molecular pathology of radiation response and toxicity. He also has major interests in the treatment of castrate-resistant prostate cancer and bone metastases in prostate cancer, and leads PROMPTS, a Phase III trial assessing the role of MR screening to prevent spinal cord compression.
Professor Dearnaley received an Excellence in Radiation Oncology Award at the European Multidisciplinary Meeting on Urological Cancers held in Barcelona in November 2011.